Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Maintenance Post-SCT in T-Cell Lymphoma
NCT07356245Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in T-cell lymphoma, graft-versus-host disease (GVHD), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
T-cell lymphomagraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07356245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356245.